e8vk
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 24, 2010
ANTHERA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-34637
|
|
20-1852016 |
|
|
|
|
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.) |
|
|
|
25801 Industrial Boulevard, Suite B, Hayward, California
|
|
94545 |
|
|
|
(Address of principal executive offices)
|
|
(Zip Code) |
Registrants telephone number, including area code: (510) 856-5600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 |
|
Departure of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers; Compensatory Arrangements of Certain Officers. |
On March 24, 2010, the Board of Directors (the Board) of Anthera Pharmaceuticals, Inc. (the
Company) adopted the Companys Executive Incentive Bonus Plan (the Bonus Plan), which applies
to certain key executive (the Executives) that are recommended by the Compensation Committee of
the Board and selected by the Board.
The Bonus Plan provides for bonus payments based upon the attainment of performance targets
established by the Board and related to financial and operational metrics with respect to the
Company or any of its subsidiaries (the Performance Goals), which would include the achievement
of clinical study or operational milestones, results of clinical studies and achievement of
specified financial metrics or objectives. Any bonuses paid under the Bonus Plan shall be based
upon objectively determinable bonus formulas that tie such bonuses to one or more performance
targets relating to the Performance Goals. The bonus formulas shall be adopted in each performance
period by the Board and communicated to each Executive. No bonuses shall be paid under the Bonus
Plan unless and until the Board makes a determination with respect to the attainment of the
performance objectives. Notwithstanding the foregoing, the Company may adjust bonuses payable
under the Bonus Plan based on achievement of individual performance goals or pay bonuses
(including, without limitation, discretionary bonuses) to Executives under the Bonus Plan based
upon such other terms and conditions as the Board may in its discretion determine.
Each Executive shall have a targeted bonus opportunity set for each performance period. The
maximum bonus payable to an Executive under the Bonus Plan is 125% of the Executives bonus
opportunity. The Performance Goals will be measured at the end of each fiscal year after the
Companys financial reports have been published or such other appropriate time as the Board shall
determine. If the Performance Goals are met, payments will be made within 30 days thereafter, and
if met for the previous fiscal year, not later than March 31. An Executive must be employed by the
Company as of the payment date in order to receive a bonus payment, provided that the Board may
make exceptions to this requirement, in its sole discretion, including, without limitation, in the
case of an Executives termination of employment, retirement, death or disability.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Date: March 29, 2010 |
Anthera Pharmaceuticals, Inc.
|
|
|
By: |
/s/ Christopher P. Lowe
|
|
|
|
Christopher P. Lowe |
|
|
|
Chief Financial Officer and
Vice President of Administration |
|
|
3